Sucampo Pharmaceuticals is marketing AMITIZA (lubiprostone) in the U.S. for Chronic Idiopathic Constipation in adults and Irritable Bowel Syndrome with Constipation in adult women 18 years and older, and is developing the drug for additional gastrointestinal disorders with large potential markets. In addition, Sucampo Pharmaceuticals has a robust pipeline of compounds with the potential to target underserved diseases affecting millions of patients worldwide. Sucampo Pharmaceuticals has two wholly owned subsidiaries: Sucampo Pharma Europe, Ltd. headquartered in Oxford, U.K., with a branch office in Basel, Switzerland, and Sucampo Pharma, Ltd., located in Tokyo and Osaka, Japan. To learn more about Sucampo Pharmaceuticals and its products, visit http://www.sucampo.com.
Takeda Pharmaceuticals North America, Inc.
Based in Deerfield, Ill., Takeda Pharmaceuticals North America, Inc. is
a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, the
largest pharmaceutical company in Japan. In the United States, Takeda
currently markets products for diabetes, insomnia, wakefulness and
gastroenterology. The company has a robust pipeline with compounds in
development for diabetes, cardiovascular disease and other conditions.
Takeda is committed to striving toward better health for individuals and
progress in medicine by developing superior pharmaceutical products. To
learn more about the company and its products, visit http://www.tpna.com.
Sucampo Pharmaceuticals, Inc.
|SOURCE Takeda Pharmaceuticals North America, Inc.; SucampoPharmaceuticals|
Copyright©2008 PR Newswire.
All rights reserved